|本期目录/Table of Contents|

[1]顾晓凌,吴冠楠,王栋,等.免疫检查点抑制剂相关甲状腺不良事件对PD-1单抗治疗非小细胞肺癌的预测价值[J].医学研究与战创伤救治(原医学研究生学报),2023,25(1):7-12.[doi:10.3969/j.issn.1672-271X.2023.01.002]
　GU Xiaoling,WU Guannan,WANG Dong,et al.Immune-related thyroid function abnormality is a prognostic factor for non-small cell lung cancer patients treated with PD-1 monoclonal antibody[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2023,25(1):7-12.[doi:10.3969/j.issn.1672-271X.2023.01.002]
点击复制

免疫检查点抑制剂相关甲状腺不良事件对PD-1单抗治疗非小细胞肺癌的预测价值()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第25卷
期数:
2023年1期
页码:
7-12
栏目:
临床研究
出版日期:
2023-05-10

文章信息/Info

Title:
Immune-related thyroid function abnormality is a prognostic factor for non-small cell lung cancer patients treated with PD-1 monoclonal antibody
作者:
顾晓凌; 吴冠楠; 王栋; 姚艳雯
作者单位：210002南京，东部战区总医院呼吸与危重症医学科（顾晓凌、吴冠楠、王栋、姚艳雯）
Author(s):
GU Xiaoling;  WU Guannan;  WANG Dong;  YAO Yanwen
(Department of Respiratory Medicine, General Hospital of Eastern Theater Command, PLA, Nanjing 210002, Jiangsu, China)
关键词:
非小细胞肺癌; 免疫检查点抑制剂; 程序性细胞死亡蛋白-1; 甲状腺功能异常
Keywords:
non-small cell lung cancer; immune checkpoint inhibitors;  programmed cell death protein 1; thyroid function abnormality
分类号:
R320.67
DOI:
10.3969/j.issn.1672-271X.2023.01.002
文献标志码:
A
摘要:
目的观察免疫检查点抑制剂相关甲状腺不良事件在接受程序性细胞死亡蛋白-1（PD-1）单抗治疗的非小细胞肺癌中的发生率、临床过程，探索其对预后的预测价值。方法回顾性分析2019年1月至2021年5月在东部战区总医院接受免疫检查点抑制剂治疗的非小细胞肺癌患者94例临床资料。评估甲状腺功能异常-免疫相关不良反应（TFA-IRAE）的发生率、临床过程、及其与无进展生存期（PFS）的关系。结果94例患者中，22例（23.4%）患者发生TFA-IRAE。TFA-IRAE组患者的中位PFS显著长于未发生TFA-IRAE组（20.23个月 vs 9.33个月；P=0.007）。多变量Cox回归分析提示TFA-IRAE的发生是PFS预后良好的独立预测因子（HR 0.44，95%CI 0.213~0.911，P=0.027）。结论TFA-IRAE与PD-1抑制剂治疗NSCLC患者的疗效相关，可能是一种抗肿瘤免疫反应的临床生物标志物。
Abstract:
ObjectiveTo observe the incidence and clinicalcourse of immune checkpoint inhibitor-related thyroid adverse events in non-small cell lung cancer (NSCLC) patients treated with programmed cell death protein-1 (PD-1) monoclonal antibody, and to explore its predictive value for prognosis.MethodsWe conducted a retrospective study of 94 NSCLC patients who were treated with PD-1 inhibitors between January 2019 and May 2021，in General Hospital of Eastern Theater Command. Frequency of development of TFA-IRAEs, its clinical course, and its relationship with progression free survival (PFS) were evaluated.Results94 NSCLC patients treated with PD-1 inhibitors were enrolled in our study. Among them, 22 patients (23.4%) developed TFA-IRAE. Kaplan-Meier analysis showed that the PFS in patients with TFA-IRAEs (20.23 months vs 9.33 months, P=0.007) was significantly longer than those in without TFA-IRAEs. Multivariable Cox regression analysis revealed that occurrence of TFA-IRAEs was an independent predictor for better PFS(adjusted hazard ratio 0.44, 95%CI 0.213-0.911, P=0.027).ConclusionTFA-IRAEs is associated with enhanced PD-1 inhibitor efficacy in NSCLC patients and it may be a clinical biomarker for antitumor immune response

参考文献/References:

[1]Zheng R, Zhang S, Zeng H, et al.Cancer incidence and mortality in China, 2016[J]. J Natl Cancer Cent,2022, 2(1):1-9.
[2]Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer[J]. N Engl J Med, 2018, 378(22):2078-2092.
[3]Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden[J]. N Engl J Med, 2018, 378(22):2093-2104.
[4]Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC[J]. N Engl J Med, 2018, 378(24):2288-2301.
[5]Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer[J]. N Engl J Med, 2015, 373(17):1627-1639.
[6]Brahmer J, Reckamp KL, Baas P, Crino L, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer[J]. N Engl J Med, 2015, 373(2):123-135.
[7]Abril-Rodriguez G, Ribas A. SnapShot: Immune Checkpoint Inhibitors[J]. Cancer Cell,2017, 31(6):848-848 e841.
[8]Khoja L, Day D, Wei-Wu Chen T, et al. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review[J]. Ann Oncol, 2017, 28(10):2377-2385.
[9]Presotto EM, Rastrelli G, Desideri I, et al. Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study[J]. J Endocrinol Invest, 2020, 43(3):337-345.
[10]Kassi E, Angelousi A, Asonitis N, et al. Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma[J]. Cancer Med, 2019, 8(15):6585-6594.
[11]Illouz F, Drui D, Caron P, et al.Expert opinion on thyroid complications in immunotherapy[J]. Ann Endocrinol (Paris),2018, 79(5):555-561.
[12]Scott ES, Long GV, Guminski A, et al.The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma[J]. Eur J Endocrinol, 2018, 178(2):173-180.
[13]Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma[J]. N Engl J Med, 2015, 373(1):23-34.
[14]Osorio JC, Ni A, Chaft JE, et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer[J]. Ann Oncol, 2017, 28(3):583-589.
[15]Campredon P, Mouly C, Lusque A, et al. Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer: Retrospective study of 105 patients[J]. Presse Med, 2019, 48(4):e199-e207.
[16]Morganstein DL, Lai Z, Spain L, et al. Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma[J]. Clin Endocrinol (Oxf),2017, 86(4):614-620.
[17]Grangeon M, Tomasini P, Chaleat S, et al. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer[J]. Clin Lung Cancer,2019, 20(3):201-207.
[18]Kim HI, Kim M, Lee SH, et al. Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer[J]. Oncoimmunology, 2017, 7(1):e1375642.
[19]Zhou Y, Xia R, Xiao H, et al. Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer[J]. Int Immunopharmacol,2021, 91:107296.
[20]Thuillier P, Joly C, Alavi Z, et al. Thyroid dysfunction induced by immune checkpoint inhibitors is associated with a better progression-free survival and overall survival in non-small cell lung cancer: an original cohort study[J]. Cancer Immunol Immunother,2021, 70(7):2023-2033.
[21]Chang LS, Barroso-Sousa R, Tolaney SM, et al.Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints[J]. Endocr Rev,2019, 40(1):17-65.
[22]Das S, Johnson DB.Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors[J]. J Immunother Cancer，2019, 7(1):306.
[23]陆舜，晋悦萍.肺癌免疫治疗进入2.0时代了吗[J]. 医学研究生学报，2017,30(11)：1128-1131.

相似文献/References:

[1]周诚忠,夏炎春,夏海波.三维适形放射治疗老年非小细胞肺癌60例[J].医学研究与战创伤救治(原医学研究生学报),2009,11(01):20.
　ZHOU Cheng-zhong,XIA Yan-chun,XIA Hai-bao.Analysis of curative effect on 60 elderly non-small cell lung cancer patients treated by three-dimensional conformal radiotherapy[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2009,11(1):20.
[2]洪原城,林平冬,张江灵,等.晚期非小细胞肺癌骨转移的骨相关事件 及生存分析[J].医学研究与战创伤救治(原医学研究生学报),2009,11(02):124.
　HONG Yuan-cheng,LIN Ping-dong,ZHANG Jiang-ling,et al.Skeletal-related events of skeletal metastases in advanced stage non-small cell lung cancer and survival analysis[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2009,11(1):124.
[3]陈芳芳 综述,李晓军 审校.细胞凋亡在介导非小细胞肺癌耐药调节中的作用[J].医学研究与战创伤救治(原医学研究生学报),2015,17(03):286.[doi:10.3969/j.issn.1672-271X.2015.03.020]
[4]周向毅,丁妍,陈邦元,等.复方康复灵对体部伽玛刀治疗非小细胞肺癌引起的急性放射反应的防护作用[J].医学研究与战创伤救治(原医学研究生学报),2015,17(05):455.[doi:10.3969/j.issn.1672-271X.2015.05.002]
　ZHOU Xiang-yi,DING Yan,CHEN Bang-yuan,et al.Protective effect of compound Kangfuling on body gamma knife in treating acute radiation reaction of non-small cell lung cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2015,17(1):455.[doi:10.3969/j.issn.1672-271X.2015.05.002]
[5]周小林.CRP和Alb与初诊断的非小细胞肺癌临床病理特征联系及预后价值分析[J].医学研究与战创伤救治(原医学研究生学报),2016,18(05):489.[doi:10.3969/j.issn.1672-271X.2016.05.012]
　ZHOU Xiao-lin.Prognostic evaluation of CRP and Alb in newly diagnosed non-small cell lung cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2016,18(1):489.[doi:10.3969/j.issn.1672-271X.2016.05.012]
[6]徐瑞彤,孙康俊,戴冠群,等.抗雌激素治疗对耐酪氨酸激酶抑制剂非小细胞肺癌细胞株抗增殖作用的机制探讨[J].医学研究与战创伤救治(原医学研究生学报),2017,19(06):581.[doi:10.3969/j.issn.1672-271X.2017.06.006]
　XU Rui-tong,SUN Kang-jun,DAI Guan-qun,et al.The antitumor effect of anti-estrogen therapy on non-small cell lung cancer cell lines with acquired resistance to EGFR-TKI[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2017,19(1):581.[doi:10.3969/j.issn.1672-271X.2017.06.006]
[7]张驰,张久荣,童维佳,等.芪胶升白胶囊对改善非小细胞肺癌患者化疗所致中性粒细胞减少症的临床药物疗效研究与分析[J].医学研究与战创伤救治(原医学研究生学报),2018,20(01):26.[doi:10.3969/j.issn.1672-271X.2018.01.006]
　ZHANG Chi,ZHANG Jiu-rong,TONG Wei-jia,et al.Study and analysis on clinical drug efficacy of Qijiaoshengbai capsule on the treatment of non-small cell lung cancer patients with neutropenia caused by chemotherapy[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2018,20(1):26.[doi:10.3969/j.issn.1672-271X.2018.01.006]
[8]沈凯凯综述,吕镗烽审校.外泌体在非小细胞肺癌中的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2018,20(04):399.[doi:10.3969/j.issn.1672-271X.2018.04.016]
[9]王毅,权琳.培美曲塞与顺铂联合吉非替尼治疗对非小细胞肺癌患者T细胞亚群及细胞因子的影响[J].医学研究与战创伤救治(原医学研究生学报),2020,22(01):43.[doi:10.3969/j.issn.1672-271X.2020.01.010]
　WANGYi,QUANLin.Effects of pemetrexed and cisplatin combined with gefitinib on T cell subsets and cytokines in patients with lung cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2020,22(1):43.[doi:10.3969/j.issn.1672-271X.2020.01.010]
[10]蔡猛,周光新.非小细胞肺癌骨转移的治疗研究进展[J].医学研究与战创伤救治(原医学研究生学报),2022,24(4):408.[doi:10.3969/j.issn.1672-271X.2022.04.015]
　CAI Meng,ZHOU Guang-xin.Research progress in the treatment of bone metastasis in non-small cell lung cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2022,24(1):408.[doi:10.3969/j.issn.1672-271X.2022.04.015]

备注/Memo

备注/Memo:
基金项目：国家自然科学基金（82002456）
更新日期/Last Update: 2023-04-19